Abstract Number: 302 • 2013 ACR/ARHP Annual Meeting
Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy: 1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Background/Purpose: Ustekinumab (UST) has demonstrated substantial efficacy and an acceptable safety profile, and is approved for use, in treating moderate-to-severe psoriasis. UST has also demonstrated…Abstract Number: 303 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Risk of Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A general population-based cohort studyBackground/Purpose: Psoriatic arthritis (PsA), psoriasis, and rheumatoid arthritis…Abstract Number: 304 • 2013 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) have been considered a relatively specific marker for rheumatoid arthritis (RA), and may play a role in its pathogenesis. In…Abstract Number: 305 • 2013 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Background/Purpose: To assess the incidence of Herpes Zoster (HZ) in patients with psoriatic arthritis (PsA) and its relation to treatment regimen:Traditional disease-modifying anti-rheumatic drugs (c-DMARDs)…Abstract Number: 306 • 2013 ACR/ARHP Annual Meeting
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Background/Purpose: Psoriatic arthritis (PsA) manifests clinically in several ways, including arthritis, enthesitis, and dactylitis,. Assessment of disease activity in PsA should ideally record each feature.…Abstract Number: 307 • 2013 ACR/ARHP Annual Meeting
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by about 10 years in patients who develop psoriatic arthritis (PsA). Several studies have documented abnormal musculoskeletal imaging findings…Abstract Number: 308 • 2013 ACR/ARHP Annual Meeting
Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
Background/Purpose: Psoriatic Arthritis (PsA) remains an under-diagnosed disease among patients with psoriasis (PsO). Dermatologists are not routinely trained to detect musculoskeletal manifestations hence arthritis, enthesitis…Abstract Number: 309 • 2013 ACR/ARHP Annual Meeting
Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis
Background/Purpose: Diagnostic delay in Psoriatic Arthritis (PsA) is not uncommon with a recent study of psoriasis patients attending a dermatology clinic showing that 29% of…Abstract Number: 310 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 1, 2, and 3 compared the efficacy and safety of…Abstract Number: 311 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 3 compared the efficacy/safety of APR with placebo (PBO) in…Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting
The DC-STAMP+IL17A+ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…Abstract Number: 315 • 2013 ACR/ARHP Annual Meeting
Long Term Outcomes In Psoriatic Arthritis 2; A Prospective Multicentre Observational Study Of Work Disability In Psoriatic Arthritis: First Report Of The Clinical and Socioeconomic Associations Of Work Disability In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that is associated with joint damage, impaired quality of life and high levels of work disability…Abstract Number: 316 • 2013 ACR/ARHP Annual Meeting
Quantiferon-TB Test Can Be Usefull For Decision Of Anti-Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life
Background/Purpose: Anti-tumor necrosis factor (TNF) treatments may increase tuberculosis. Most of the national guidelines recommend tuberculin skin test (TST) for screening of latent tuberculosis. However,…Abstract Number: 317 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…
ACR Meeting Abstracts